Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial
Authors:
- Giuseppe DerosaGDGiuseppe Derosa
- Arrigo F.G CiceroACArrigo F.G Cicero
- Antonio GaddiAGAntonio Gaddi
- Pietro D RagonesiPRPietro D Ragonesi
- Elena FogariEFElena Fogari
- Gianandrea BertoneGBGianandrea Bertone
- Leonardina CiccarelliLCLeonardina Ciccarelli
- Mario N PiccinniMPMario N Piccinni
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (5) , 744-754
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Thiazolidinediones – some recent developmentsExpert Opinion on Investigational Drugs, 2003
- Thiazolidinediones in Type 2 Diabetes MellitusDrugs, 2003
- ThiazolidinedionesSouthern Medical Journal, 2002
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002
- Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by PioglitazoneCurrent Medical Research and Opinion, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Clinical review of glimepirideExpert Opinion on Pharmacotherapy, 2001
- The Glycosylation of Hemoglobin: Relevance to Diabetes MellitusScience, 1978
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955